Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
delayed orgasm.
Popular Articles

New Family-Focused Model Of Depression Care Needed To Minimize Risks And Problems For Parents With Depression And Their Children
Health and social service professionals who care for adults with depression should not only tackle their clients" physical and mental health, but also detect and prevent possible spillover effects on their children, says a new report from the National Research Council and Institute of Medicine. To achieve this new family-focused model of depression care, federal and state agencies, nonprofits, and the private sector will have to experiment with nontraditional ways of organizing, paying for, and delivering services, said the committee that wrote the report.
generic viagra
Fuel Up For Fun Wins National Food And Healthy Living Award
Dietitians of Canada and Kraft Canada have announced the winners of the 12th annual Speaking of Food and Healthy Living Award - an annual competition designed to showcase and encourage collaborative efforts that help Canadians make informed choices about healthy eating and physical activity.
News of the day
Israeli Startup CLT Partners With Dutch Erasmus Medical Centre To Develop A Cure For Atrial Fibrillation
Today, the Israeli medtech startup company CLT Ltd. announced the establishment of Closed Loop Therapies (CLT) BV - a joint venture between Erasmus University Medical Centre (Rotterdam, the Netherlands), a highly prominent medical institute in Europe, and CLT Israel. The joint venture aims to develop and commercialise a novel therapeutic system, consisting of an arrhythmia-detecting drug pump combined with a unique drug, for automatic and immediate treatment of emerging atrial fibrillation (AF). Market size is estimated at 2.5-3 billion Euro, annually.
Sexual Health

Accumetrics, Inc. Announces 1000th Patient Enrolled In GRAVITAS Trial

Accumetrics, Inc. announces that it has enrolled its 1,000th patient into its landmark clinical trial, GRAVITAS (Gauging Responsiveness with A VerifyNow(R) Assay Impact on Thrombosis And Safety). The trial is specifically designed to demonstrate the value of providing clinicians with actionable information for patients who are poor responders to clopidogrel (Plavix(R)). The multi-center, placebo controlled trial will determine whether tailored antiplatelet therapy for poor responders, identified based on the results of the company"s VerifyNow P2Y12 Test, reduces major cardiovascular adverse events (e.g., heart attack, stent thrombosis) following percutaneous coronary intervention (PCI). Currently the trial is being conducted at more than 70 sites in the U.S. and Canada, with a total enrollment goal of approximately 2,800 patients. "This is a very significant milestone for Accumetrics as it brings us ever-closer to our goal of demonstrating the value of the VerifyNow System. By identifying and adjusting therapy for patients that are not responding adequately to standard doses of clopidogrel, GRAVITAS will be the largest multi-center clinical trial that links testing with personalized medicine and improved outcomes. We believe that the VerifyNow System will be seen as an integral tool in ensuring that patients receive not only the most appropriate antiplatelet therapy, but also the adequate dose," said Jeff Dahlen, Ph.D, Vice President, Clinical and Regulatory Affairs of Accumetrics, Inc. "We are very proud to reach this milestone, and look forward to completing enrollment soon, and sharing the results." About GRAVITAS The concept of variability in response to antiplatelet therapy has been well established. The question of whether poor response to antiplatelet therapy, as measured by a laboratory test, leads to poor outcomes is also being demonstrated with increased frequency. However, Accumetrics recognizes the need for a study specifically designed to demonstrate the value of providing clinicians with actionable information to improve outcomes for those patients who are poor responders to antiplatelet therapy. As a result, the GRAVITAS study is the first multi-center, placebo-controlled study to determine whether tailored antiplatelet therapy based on the results of the company"s VerifyNow System reduces major cardiovascular adverse events post-PCI. Accumetrics, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009